Followers | 183 |
Posts | 25218 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Wednesday, April 05, 2023 3:51:02 PM
From the news:
Vered Caplan, CEO of Orgenesis, said, “I am pleased to report that revenue for the fourth quarter of 2022 increased by 98% to $13.6 million, compared to $6.9 million for the same period last year as we are progressing with the planned rollout of our POCare platform. In addition to our strong revenue growth, we reduced our operating loss by 91% for the fourth quarter of 2022 versus the same period last year, which reflects our cost-effective and highly scalable business model. The goal of our Orgenesis Mobile Processing Units and Labs (OMPUL) strategy is to provide autologous cell and gene therapies to patients in need at the point-of-care, which, in turn, is expected to dramatically lower costs. Our latest investments have allowed us to increase our capacity and advance our go-to-market strategy as we aim to expand the deployment of our Orgenesis Mobile Processing Units and Labs (OMPULs). Most recently, we signed a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis) to deploy our OMPULs at UC Davis and other healthcare universities within the State of California. Additionally, we are focused on supporting the POCare Centers located at strategic locations in various countries across North America, Europe, Asia, and the Middle East, which serve as hubs for the respective regions.”
Ms. Caplan continued, “Orgenesis is also advancing our POCare therapeutic pipeline, while leveraging grants and partnerships. In 2022, our subsidiary, Koligo Therapeutics, supplied Kyslecel to five medical institutes supplying total pancreatectomy - islet auto transplant (TP-IAT) cases. Production from this one site enabled Koligo to achieve positive cash flow from operations in the fourth quarter of the year as a separate business unit. Additionally, Koligo passed an FDA inspection of this site as a registered tissue production establishment in February. Following this confirmation of the infrastructure design and production protocols, and building on increasing demand, we are now pursuing plans for site expansion in the US and internationally. In the EU, Koligo is utilizing the expertise of Orgenesis to enable regional production capacity and leverage grants to drive clinical development towards marketing approval.”
The complete financial results for the fourth quarter and year ended December 31, 2022 are available on the Company’s website in the Company’s Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission.
Recent ORGS News
- Orgenesis Announces Reverse Stock Split • GlobeNewswire Inc. • 09/23/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 12:30:47 PM
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia • GlobeNewswire Inc. • 08/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:05:13 PM
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Orgenesis Provides Second Quarter 2024 Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 03:25:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 12:45:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/14/2024 04:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 10:14:05 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/24/2024 01:16:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:00:31 PM
- Orgenesis Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/21/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:01:42 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:01:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 07:28:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 07:26:43 PM
- Orgenesis Provides Year End Business Update • GlobeNewswire Inc. • 04/15/2024 09:07:16 PM
- Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility • GlobeNewswire Inc. • 04/10/2024 04:00:00 PM
- Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM